Human Reproduction, Vol. 16, No. 6, 1104-1109,
June 2001
© 2001 European Society of Human Reproduction and Embryology
A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles
1 Organon Laboratories, Cambridge Science Park, Cambridge, UK, 2 IVF Unit, Carmel Medical Centre, Haifa, 3 IVF Unit, Assaf Harofeh Medical Centre, Zerifin, 4 HaEmek Medical Centre, IVF Unit, Afula, 5 Department of Obstetrics and Gynaecology, Sheba Medical Centre, Tel-Hashomer, and 6 Rabin Medical Centre, Campus Beilinson, Petach Tiqva, Israel
The effect of 100 and 200 IU per day recombinant FSH (rFSH) on numbers of oocytes retrieved and the total dose used in ovarian stimulation before intracytoplasmic sperm injection was investigated in a double-blind, randomized multicentre trial. A total of 91 women was treated with a low-dose protocol and 88 with a high-dose regimen at five centres. For each started cycle, significantly more oocytes were retrieved in the 200 IU group than in 100 IU group (12.0 versus 5.7, P < 0.001); total rFSH consumption was 1121 and 1875 IU in the low- and high-dose groups respectively. Significant variations were noted between centres with regard to numbers of oocytes collected per started cycle, ranging from 2.8 to 7.2 in the 100 IU group and from 9.0 to 19.1 in the high-dose group. Exploratory analyses of secondary outcomes suggested there were no differences in vital pregnancy rates per started cycle (19.2 versus 16.9%) and per embryo transfer (26.2 versus 19.3%) in the low- and high dose groups respectively. There were four hospitalizations due to ovarian hyperstimulation syndrome, all in the 200 IU group.
Key words: ICSI/IVF/Puregon/randomized clinical trial/recombinant FSH
7 To whom correspondence should be addressed at: Organon Laboratories, Cambridge Science Park, Milton Road, Cambridge CB4 0FL, UK. E-mail: h.out{at}organon.cge.akzonobel.nl
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Devroey, B.C.J.M. Fauser, K. Diedrich, and on behalf of the Evian Annual Reproduction (EVAR) Approaches to improve the diagnosis and management of infertility Hum. Reprod. Update, July 1, 2009; 15(4): 391 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.F.G. Verberg, N.S. Macklon, G. Nargund, R. Frydman, P. Devroey, F.J. Broekmans, and B.C.J.M. Fauser Mild ovarian stimulation for IVF Hum. Reprod. Update, January 1, 2009; 15(1): 13 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.C.J.M. Fauser, K. Diedrich, P. Devroey, and on behalf of the Evian Annual Reproduction (EVAR) Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation Hum. Reprod. Update, January 1, 2008; 14(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Trew Comparing highly purified hMG and rFSH in patients undergoing IVF Hum. Reprod., June 1, 2007; 22(6): 1797 - 1798. [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kwee, R. Schats, J. McDonnell, C.B. Lambalk, and J. Schoemaker Intercycle variability of ovarian reserve tests: results of a prospective randomized study Hum. Reprod., March 1, 2004; 19(3): 590 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, A. Rutherford, R. Fleming, C. C.K. Tay, G. Trew, W. Ledger, and D. Cahill A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction Hum. Reprod., January 1, 2004; 19(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Popovic-Todorovic, A. Loft, H.E. Bredkjaeer, S. Bangsboll, I.K. Nielsen, and A.N. Andersen A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment Hum. Reprod., November 1, 2003; 18(11): 2275 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kwee, M.W. Elting, R. Schats, P.D. Bezemer, C.B. Lambalk, and J. Schoemaker Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study Hum. Reprod., July 1, 2003; 18(7): 1422 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Popovic-Todorovic, A. Loft, A. Lindhard, S. Bangsboll, A.M. Andersson, and A.N. Andersen A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram Hum. Reprod., April 1, 2003; 18(4): 781 - 787. [Abstract] [Full Text] [PDF]
|
|